Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Methods to Increase Stability of Recombinant Vaccinia-Vectored Vaccines and Increase Expression of a Foreign Gene Inserted in Su

Posted Feb 28 2010 4:00pm

Description of Invention:
The technology offered for licensing is in the field of vaccinia-based recombinant vaccines. In particular the invention relates to methods of stabilizing the recombinant virus, thus resulting in efficient production of the vaccine and efficient expression of the inserted gene. Stabilization of the recombinant virus is achieved by the insertion of the exogenous gene into an intergenic region (IGR) of the viral genome (i.e. Modified Vaccinia Ankara, MVA), where the IGR is flanked by open reading frames of conserved poxvirus genes. Furthermore, the invention relates to plasmids vectors useful to insert the exogenous DNA into the genome of a vaccinia virus. Stability can be further enhanced by incorporating silent mutations that decrease the lengths of homopolynucleotide runs in the foreign gene.

Applications:
  • Efficient production of vaccinia-vectored vaccines for infectious diseases and other diseases such as cancer
  • Efficient production of therapeutic proteins from vaccinia-vectored exogenous genes


Advantages:
  • Enhancing stability of foreign genes in vaccinia-vectored constructs
  • Increasing efficiency of vaccine production and gene expression


Development Status:
The invention is fully developed.

Inventors:
Bernard Moss (NIAID)


Patent Status:
HHS, Reference No. E-018-2010/0
US, Application No. 61/252,326 filed 16 Oct 2009


Related Technologies:
US, Application No. 12/377,847 filed 17 Feb 2009, Reference No. E-248-2006/0
US, Patent No. 7,045,313, Issued 16 May 2006, Reference No. E-552-1982/2
US, Patent No. 7,015,024, Issued 21 Mar 2006, Reference No. E-552-1982/2
US, Patent No. 6,998,252, Issued 14 Feb 2006, Reference No. E-552-1982/2
US, Patent No. 7,045,136, Issued 16 May 2006, Reference No. E-552-1982/2
US, Application No. 60/840,093 filed 25 Aug 2006, Reference No. E-248-2006/0
PCT, Application No. PCT/IB2007/004575 filed 24 Aug 2007, Reference No. E-248-2006/0
PCT, Application No. PCT/US83/01863 filed 28 Nov 1983, Reference No. E-552-1982/2


Relevant Publication:
  1. LS Wyatt, PL Earl, W Xiao, J Americo, C Cotter, J Vogt, B Moss. Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selections. J Virol. 2009 Jul;83(14):7176-7184. [ PubMed: 19420086 ]


Licensing Status:
Available for licensing.


Portfolios:
Gene Based Therapies
Gene Based Therapies - Therapeutics



For Additional Information Please Contact:
John Stansberry Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: js852e@nih.gov
Phone: 301-435-5236
Fax: 301-402-0220


Ref No: 2068

Updated: 03/2010

Post a comment
Write a comment:

Related Searches